



IARC Monographs on the Identification of Carcinogenic Hazards to Humans

Volume 137: Hydrochlorothiazide, Voriconazole, and Tacrolimus

Lyon, France: 5–12 November 2024

LIST OF PARTICIPANTS

Working Group Members served in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

Members

Alexandra Antunes, Instituto Superior Técnico (IST), University of Lisbon, Portugal

Elizabeth Cahoon, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics,
National Cancer Institute, USA

Guosheng Chen, Health Products and Food Branch, Health Canada, Canada

Vincent Coglianò, Office of Environmental Health Hazard Assessment, California Environmental
Protection Agency (retired), USA

Emanuela Corsini, Department of Pharmacological and Biomolecular Sciences (DISFEB), University of
Milan, Italy

Talita Duarte Salles, Erasmus Medical Center, Institut d'investigació en Atenció Primària de Salut Jordi
Gol (IDIAPJGol), Spain

Eric Engels, Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, USA

Agnès Fournier, Centre de recherche en Épidémiologie et Santé des Populations, Institute Gustave
Roussy, Université Paris-Saclay, France

Jingqi Fu, School of Public Health, China Medical University, China

Dori Germolec, Division of Translational Toxicology, National Institute of Environmental Health
Sciences, USA

Reza Ghiasvand, Oslo University Hospital and Cancer Registry of Norway, Norway

Blánaid Hicks, Centre for Public Health, Queen's University Belfast, UK

Bertrand J Jean-Claude, Department of Medicine, McGill University, Canada

Gopabandhu Jena, Department of Pharmacology and Toxicology, National Institute of
Pharmaceutical Education and Research (NIPER), India

Catharina M Lerche, Copenhagen University Hospital Bispebjerg, University of Copenhagen, Denmark

Xilin Li, National Center for Toxicological Research, United States Food and Drug Administration, USA


Angela Lupattelli, Department of Pharmacy, University of Oslo, Norway

Heather Nelson, Division of Epidemiology & Community Health, University of Minnesota, USA

Thomas Prates Ong, Faculty of Pharmaceutical Sciences, University of São Paulo, Brazil

Consolato Sergi, Children's Hospital of Eastern Ontario, University of Ottawa, Canada

Libia Vega Loyo, Center for Research and Advanced Studies of the National Polytechnic Institute,
Mexico



Diana Withrow, Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, UK

Invited Specialists

Alistair BA Boxall, Environment Department, University of York, UK¹

Representatives of national and international health agencies

Elena María Doménech Cruz, Carlos III Health Institute (ISCIII), Ministry of Science, Innovations and Universities, Spain (withdrew)

Observers

None

IARC Secretariat

Lamia Benbrahim-Tallaa, *IARC Monographs Programme*

Aline de Conti, *IARC Monographs Programme*

Xiaobei Deng, *IARC Monographs Programme*

Caterina Facchin, *IARC Monographs Programme (Co-Responsible Officer)*

Andrew Kunzmann, *IARC Monographs Programme*

Federica Madia, *IARC Monographs Programme (Responsible Officer)*

Yahya Mahamat Saleh, Nutrition and Metabolism Branch

Azam Majidi, Nutrition and Metabolism Branch

Heidi Mattock, *IARC Monographs Programme*

Elisa Pasqual, *IARC Monographs Programme*

Laia Peruchet Noray, Nutrition and Metabolism Branch

Julia Rezende Da Silva, *IARC Monographs Programme*

Mary Schubauer-Berigan, *IARC Monographs Programme (Programme Head)*


Eero Suonio, *IARC Monographs Programme*

Susana Viegas, *IARC Monographs Programme*

Roland Wedekind, *IARC Monographs Programme*

Yue Zhai, Nutrition and Metabolism Branch

¹Dr Boxhall reports that his unit benefits from research funding from Haleon and AMR industry alliance. This was determined not to present a conflict of interest for the present IARC Monographs meeting, since both groups have no reported involvement with the agents under review. He also reports research funding from his unit that comes from Sandoz Pharmaceuticals, which markets two of the agents under review (voriconazole and tacrolimus) at the present meeting.



NOTE REGARDING CONFLICTS OF INTERESTS: Each participant first received a preliminary invitation with the request to complete and sign the IARC/WHO Declaration of Interests, which covers employment and consulting activities, individual and institutional research support, and other financial or non-financial interests (e.g. public statements and positions related to the subject of the meeting).

Official invitations were extended after careful assessment of any declared interests that might constitute a conflict of interest. Pertinent and significant conflicts are disclosed here. Information about other potential conflicts that are not disclosed may be sent to the Head of the *IARC Monographs* programme at imo@iarc.who.int.

Participants identified as Invited Specialists did not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data or participate in the evaluations. The Declarations were updated and reviewed again at the opening of the meeting.

Posted on 6 November 2024